Primary Care COPD Patients Compared with Large Pharmaceutically-Sponsored COPD Studies : An UNLOCK Validation Study
Annemarije L Kruis,Björn Ställberg,Rupert Jones,Ioanna Tsiligianni,Karin Lisspers,Thys van der Molen,Janwillem W. H. Kocks,Niels H. Chavannes +7 more
Reads0
Chats0
TLDR
Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations, as hitherto unknown GOLD I exacerbation characteristics are revealed.Abstract:
Background: Guideline recommendations for chronic obstructive pulmonary disease (COPD) are based on the results of large pharmaceutically-sponsored COPD studies (LPCS). There is a paucity of data on disease characteristics at the primary care level, while the majority of COPD patients are treated in primary care. Objective: We aimed to evaluate the external validity of six LPCS (ISOLDE, TRISTAN, TORCH, UPLIFT, ECLIPSE, POET-COPD) on which current guidelines are based, in relation to primary care COPD patients, in order to inform future clinical practice guidelines and trials. Methods: Baseline data of seven primary care databases (n = 3508) from Europe were compared to baseline data of the LPCS. In addition, we examined the proportion of primary care patients eligible to participate in the LPCS, based on inclusion criteria. Results: Overall, patients included in the LPCS were younger (mean difference (MD)-2.4; p = 0.03), predominantly male (MD 12.4; p = 0.1) with worse lung function (FEV1% MD -16.4; p = 1 and >= 2 exacerbations, although results were not statistically significant. Our findings add to the literature, as we revealed hitherto unknown GOLD I exacerbation characteristics, showing 34% of mild patients had >= 1 exacerbations per year and 12% had >= 2 exacerbations per year. The proportion of primary care patients eligible for inclusion in LPCS ranged from 17% (TRISTAN) to 42% (ECLIPSE, UPLIFT). Conclusion: Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations. More research is needed to determine the effect of pharmacological treatment in mild to moderate patients. We encourage future guideline makers to involve primary care populations in their recommendations.read more
Citations
More filters
Journal ArticleDOI
Effectiveness trials : critical data to help understand how respiratory medicines really work?
TL;DR: Effectiveness data hold the potential to address several evidentiary gaps related to the effectiveness, safety, and value of treatments in patients with respiratory diseases, as well as provide examples from therapeutic areas.
Journal ArticleDOI
Follow-up interviews from The Salford Lung Study (COPD) and analyses per treatment and exacerbations
Diane Whalley,Henrik Svedsater,Lynda C. Doward,Rebecca Crawford,David Leather,James Lay-Flurrie,Nick Bosanquet +6 more
TL;DR: Initiation of FF/VI was associated with a greater perceived improvement in patients’ control of their COPD and QoL throughout SLS COPD than continuation of UC, and suggestions that smoking status and feelings of control are potentially related to exacerbation require further investigation.
Journal ArticleDOI
Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials.
TL;DR: In this pooled analysis of RCT data, once-daily UMEC/VI was well tolerated and provided clinically significant lung function benefits compared with placebo in younger and older patients with COPD.
Journal ArticleDOI
Dual bronchodilation for the treatment of COPD: From bench to bedside
TL;DR: The ability of dual bronchodilation with FDCs of LAMA/LABA to prevent or reduce the risk of COPD exacerbations remains unclear due to conflicting data from large RCTs, despite several mechanisms explaining why such combinations should be of value in decreasing the frequency of COPd exacerbations.
Journal ArticleDOI
Fighting chronic lung diseases on a national level: The Dutch national action programme
Jaco Biewenga,Huib A. M. Kerstjens,Michael R. Rutgers,Emiel Rolink,Ingrid van der Gun,Guusje ter Horst,Niels H. Chavannes +6 more
TL;DR: To achieve the objectives, the Lung Alliance Netherlands presented various key activities and strategies that are described in this paper, and their mutual reinforcement is expected to have a beneficial impact on the burden of chronic lung diseases.
References
More filters
Journal ArticleDOI
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo,Suzanne S. Hurd,Alvar Agusti,Paul W. Jones,Claus Vogelmeier,Antonio Anzueto,Peter J. Barnes,Leonardo M. Fabbri,Fernando J. Martinez,Masaharu Nishimura,Robert A. Stockley,Don D. Sin,Roberto Rodriguez-Roisin +12 more
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Journal ArticleDOI
Global initiative for chronic obstructive lung disease.
Lynn B. Gerald,William C. Bailey +1 more
TL;DR: Representatives from many countries serve as a network for the dissemination and implementation of programs for diagnosis, management, and prevention of COPD.
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
The St George's Respiratory Questionnaire.
TL;DR: The St George's Respiratory Questionnaire is a standardized self-completed questionnaire for measuring impaired health and perceived well-being in airways disease and the background and rationale for its development are discussed together with an analysis of its performance.
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.